Skip to main content
Chief Investment Officers (CIOs) & Senior Allocators | Institutional Capital Advisory Council Member

Chief Investment Officers (CIOs) & Senior Allocators | Institutional Capital Advisory Council Member

skgp strategic partnersColumbia, MO

3 days ago

Apply for this role (opens in a new tab)
SKGP Healthcare Holdings | Institutional Capital Advisory Council Development horizon: 2026 to 2037 Ongoing engagement and prospective appointments for institutional CIOs and senior allocators Company we are buildingSKGP is developing a holding company to acquire and build clinics, diagnostic services and laboratories, improve their operations and retain them for the long term. Earnings would support further acquisitions, with hospitals entering the scope as the company develops. Aurune is the operating business being developed to support that strategy. Its technology and shared service teams would remove repetitive administrative work, help clinicians spend more time delivering care and make better use of existing facilities. It would serve acquired businesses and earn revenue from independent providers. Horizon would give patients and participating organisations access to those services. The company would keep improving and acquiring, applying lessons from each business to the next. We are forming an Institutional Capital Advisory Council to help shape its acquisition strategy, financing and institutional relationships. Work Aurune would remove A clinic can have an electronic medical record and still rely on people to print forms, chase signatures, locate outside records and call other departments. Patients become messengers between organisations. Physicians receive requests requiring someone to reconstruct the history before a clinical decision. The clinic pays for that coordination, while care waits for it to finish. We aim to eliminate repeated form filling and unnecessary handoffs, then manage the coordination that remains. Aurune would combine supervised AI with shared teams that obtain missing information, resolve exceptions and complete work across organisations. For medical leave, Horizon could reuse information supplied by the patient, route employment details to the authorised employer representative and prepare the medical section for the clinician’s review. Following approval, Aurune would deliver the completed document and confirm receipt. Each participant would see information relevant to their role. This would extend to referrals, prescription requests, prior authorisation and scheduling. Where another organisation still requires a call, paper document or fax, shared teams would handle that exchange behind the interface. Patients and clinical staff could see what has happened, what remains outstanding and who must act. Horizon would preserve that continuity across providers, bringing records, results and ongoing requests into a personal account that follows the patient. Acquisitions, operating improvement and reinvestment In an acquired clinic, completing referrals and preparing records before appointments could reduce delays and unused capacity. Removing repeated administrative tasks could free staff for patient support and give physicians more time for clinical work. We would measure progress through completed referrals, appointment availability, staff time per request, collection performance and care quality. Purchase price, implementation costs and financing would determine whether improvements produce an attractive return. Further acquisitions could use systems and service teams already developed within the group. Development costs would be spread across more businesses, while experience from each site would inform improvements elsewhere. Aurune would also offer software, implementation and operating services to outside facilities. The group would capture cash flow from care delivery and value from the technology and service business supporting it. Available cash could be reinvested in equipment, additional clinical services and further acquisitions. Ownership and institutional capital The proposed holding structure allows that process to continue beyond a conventional fund term. Investors would own an interest in a company intended to keep acquiring, improving and reinvesting. Capital could enter through successive financings as opportunities and operating results develop. Retained earnings would fund part of the growth, supplemented by equity or debt where the expected returns justify it. Council members would help determine the acquisition pace, financing terms and reinvestment priorities. Potential public market access forms part of the longer term strategy. A listing could broaden access to acquisition capital and create opportunities for shareholder liquidity while the operating businesses remain within the group. Expanding the care we can provide An established network of clinics, laboratories and clinical teams could introduce new diagnostics and treatments. A therapy may require specialist facilities, trained staff, reliable patient coordination and a payment arrangement that makes delivery viable. We would examine acquisitions, new facilities, licensing agreements and partnerships with biotechnology developers to assemble those requirements. As evidence and approvals permit, Aurune could support the patient pathway around those services. Successive advances in medicine would expand what the business can offer, supported by facilities and operating capabilities developed over time. Council participation We welcome CIOs and senior allocators from pension funds, endowments, family offices and sovereign wealth funds, alongside experienced public market investors and other capital allocation professionals. Members will work with the founder across four areas: Acquisitions. Establish selection criteria, review opportunities and assess the operating changes required to justify an investment. Financing and reinvestment. Shape capital structures, acquisition pacing and reinvestment in existing businesses and further growth. Institutional relationships. Develop and present the investment case, facilitate introductions and support discussions with prospective capital partners, including internal presentations where authorised. Financial development. Advise on reporting, governance, larger financing transactions and preparations for potential public market access. Appointments are nonexecutive and may sit alongside existing responsibilities, subject to employer approval. Scope and participation terms will be agreed individually; institutional investment decisions remain with the organisations concerned. Recruitment is ongoing. Alongside council appointments, we are identifying healthcare bankers and acquisition professionals for sourcing and transaction execution, with clinical, technical and operating leaders supporting implementation. Founder and principal The founder and principal has experience in clinical support, healthcare administration and scientific study, with interests spanning finance, biochemistry, immunology, organic and inorganic chemistry, and macromolecular structure. Connecting science with capital allocation, in his view, better reflects an interconnected world and can create value for investors. Preparation for a possible MD or DO pathway is intended to strengthen the initiative’s scientific and clinical foundation. Project development and company engagement Healthcare operations Hospital and clinic experience informed Aurune’s development. Its proposal has been shared with health system leadership, alongside implementation discussions with healthcare technology companies. Chilean copper developmentSKGP sourced a company advancing three copper projects in northern Chile and developed an investment thesis through direct engagement with its founder. The assets include a property approximately 22 kilometres west of Escondida and another along the mineral belt hosting Collahuasi. Exploration combines mineral chemistry and copper isotope analysis with geophysical modelling and machine learning to guide drilling toward buried porphyry systems. These methods help interpret the chemical traces and physical structure left by the fluids that deposited copper. BHP estimates US$5.4 billion to US$6.3 billion of investment for Escondida’s proposed new concentrator, providing annual copper production capacity of 230,000 to 270,000 tonnes. This illustrates the development scale of a major copper asset. Our research examined the geological confirmation, resource definition and financing needed to advance an exploration asset. Québec copper and precious metals Materials shared by the chief executive informed research into a Québec developer holding approximately 330 km² of claims. Its principal copper discovery contains an indicated resource of 4.145 million % copper equivalent, reflecting the combined value of copper and other metals under stated assumptions. A borehole muon imaging programme uses naturally occurring particles to map differences in rock density, supported by AI analysis to help interpret buried mineralisation. Separately, SGS laboratory tests recovered up to 98.9% of the copper into concentrate grading above 25% copper. The research connects exploration with metallurgy and the amount of saleable metal a processing circuit could recover. Mitochondrial medicine An investigational programme introduced to SKGP is exploring transplantation of donor mitochondria to restore cellular energy function, initially targeting amyotrophic lateral sclerosis, or ALS. Published laboratory research found that mitochondria isolated from frozen donor cells retained function comparable to those obtained from fresh cells, supporting cell banking for preparation at treatment sites. Our review examined the biological function, manufacturing consistency and clinical evidence needed to progress toward treatment delivery.

Also on the board Same function, level within a rung

Level

Director

Location

Columbia, MO

Occupation

Medical and Health Services Managers

Industry

Offices of Physicians

Posted

3 days ago

Apply for this role (opens in a new tab)